An interventional study of Shockwave therapy and Emollients & corticosteroids in Neurodermatitis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-09.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
The purpose of this study is to evaluate the therapeutic effect of shockwave therapy on reducing pruritus in neurodermatitis patients.
Based on the occurrence of side effects caused by conventional medication for prolonged employment, dermatologists and patients show solicitude for multifaceted effective methods to control the chronic and relapsing nature of neurodermatitis.
Although new modalities are continuously coming up for pruritus, there remains a great gap for providing symptom relief.
Furthermore, there is a lack in the quantitative knowledge and information in the published studies about benefits of shockwave therapy on the treatment of pruritus in neurodermatitis patients. So, this study is designed to outline the therapeutic efficacy of shockwave therapy on the treatment of pruritus in neurodermatitis patients.
22 studies on the registry are indexed under Neurodermatitis; 3 are open to participants now.
This study's enrollment of 34 is below the median of 44 across 22 interventional studies indexed under Neurodermatitis.
Browse Neurodermatitis studies →Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
It will include 17 patients suffering from neurodermatitis who will receive shockwave therapy for 10min, 4 sessions, once per week and emollients \& corticosteroids for a month.
Device: Shockwave therapy · Drug: Emollients & corticosteroids
It will include 17 patients suffering from neurodermatitis who will receive their emollients \& corticosteroids only for a month.
Drug: Emollients & corticosteroids
The procedures for Extracorporeal Shockwave Therapy (ESWT) involve several steps. First, the patient is positioned comfortably, and the physiotherapist explains the treatment procedure. Before the session begins, the device cables are checked for proper functioning. The shockwave type used is Non-Focused/Radial, with a treatment duration not exceeding 10 minutes. The frequency is set at 4 Hz, and the intensity ranges from 0.05 to 0.20 mJ/mm². Each session involves a total of 1000 to 2000 shocks. The treatment consists of four sessions, each held once a week.
Patients in both groups will receive emollients \& corticosteroids for one month.
5-D Itching Scale
The 5-D Itching Scale will be used to assess the improvement of cases by evaluating pruritus severity. Patients will complete the scale both before starting the treatment and at four sessions following the treatment. The following steps will be followed during the assessment: the patient will be positioned comfortably (sitting position), the physiotherapist will explain the pruritus symptoms score to the patient, and the patient will determine their points on the 5-D itch scale.
Time frame: one month
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.